Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Denise, Madeddu"'
Autor:
Roberta Minari, PhD, Samuel Valentini, MSc, Denise Madeddu, PhD, Andrea Cavazzoni, PhD, Silvia La Monica, PhD, Costanza Anna Maria Lagrasta, MSc, Roberto Bertorelli, MSc, Veronica De Sanctis, PhD, Paola Fassan, MSc, Cinzia Azzoni, PhD, Lorena Bottarelli, PhD, Caterina Frati, PhD, Letizia Gnetti, MD, Francesco Facchinetti, MD, Pier Giorgio Petronini, PhD, Roberta Alfieri, PhD, Alessandro Romanel, PhD, Marcello Tiseo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100278- (2022)
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-positive lung adenocarcinoma with
Externí odkaz:
https://doaj.org/article/e7a0f0aaa4584907a17791252608959c
Autor:
Silvia La Monica, Roberta Minari, Daniele Cretella, Lisa Flammini, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Graziana Digiacomo, Maricla Galetti, Denise Madeddu, Angela Falco, Costanza Annamaria Lagrasta, Anna Squadrilli, Elisabetta Barocelli, Alessandro Romanel, Federico Quaini, Pier Giorgio Petronini, Marcello Tiseo, Roberta Alfieri
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-12 (2019)
Abstract Background The third generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) osimertinib has been initially approved for T790M positive Non-Small Cell Lung Cancer (NSCLC) and more recently for first-line treatment
Externí odkaz:
https://doaj.org/article/0332689cda2e4440a52ebd48a300166b
Autor:
Giulia Mazzaschi, Gianluca Milanese, Paolo Pagano, Denise Madeddu, Letizia Gnetti, Francesca Trentini, Angela Falco, Caterina Frati, Bruno Lorusso, Costanza Lagrasta, Roberta Minari, Luca Ampollini, Mario Silva, Nicola Sverzellati, Federico Quaini, Giovanni Roti, Marcello Tiseo
Publikováno v:
Data in Brief, Vol 31, Iss , Pp 105781- (2020)
The immune regulation of cancer growth and regression has been underscored by the recent success of immunotherapy. The possibility that immune microenvironmental factors may impact on clinical outcome and treatment response still requires intense inv
Externí odkaz:
https://doaj.org/article/372c541341f747979dbd6d318d5721e8
Autor:
Benedetta Pellegrino, Giulia Mazzaschi, Denise Madeddu, Cristina Mori, Costanza Anna Maria Lagrasta, Gabriele Missale, Federico Quaini, Antonino Musolino
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
A patient with HER2-positive early breast cancer (BC) developed dermatomyositis (DM), which disappeared after the first administration of adjuvant trastuzumab. No HER2 overexpression/amplification was observed in DM skin biopsies. Both BC and skin im
Externí odkaz:
https://doaj.org/article/4319cf88ce624ce39f6ca1777cbdfdd6
Autor:
Valentina Coccè, Silvia La Monica, Mara Bonelli, Giulio Alessandri, Roberta Alfieri, Costanza Annamaria Lagrasta, Denise Madeddu, Caterina Frati, Lisa Flammini, Daniela Lisini, Angela Marcianti, Eugenio Parati, Francesca Paino, Aldo Giannì, Giampietro Farronato, Angela Falco, Lorenzo Spaggiari, Francesco Petrella, Augusto Pessina
Publikováno v:
Cells, Vol 10, Iss 6, p 1427 (2021)
Background: Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that has a significant incidence related to asbestos exposure with no effective therapy and poor prognosis. The role of mesenchymal stromal cells (MSCs) in cancer is controversia
Externí odkaz:
https://doaj.org/article/5043b2f15724475d949474c94b0dbd6f
Autor:
Mara A. Bonelli, Graziana Digiacomo, Claudia Fumarola, Roberta Alfieri, Federico Quaini, Angela Falco, Denise Madeddu, Silvia La Monica, Daniele Cretella, Andrea Ravelli, Paola Ulivi, Michela Tebaldi, Daniele Calistri, Angelo Delmonte, Luca Ampollini, Paolo Carbognani, Marcello Tiseo, Andrea Cavazzoni, Pier Giorgio Petronini
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 8, Pp 637-648 (2017)
Malignant pleural mesothelioma (MPM) is a progressive malignancy associated to the exposure of asbestos fibers. The most frequently inactivated tumor suppressor gene in MPM is CDKN2A/ARF, encoding for the cell cycle inhibitors p16INK4a and p14ARF, de
Externí odkaz:
https://doaj.org/article/3cdb3d2e6caf46e68e613ac77ece5f9b
Autor:
Andrea Ardizzoni, Pier Giorgio Petronini, Marcello Tiseo, Claudia Fumarola, Pietro Rossetti, Angela Falco, Costanza Annamaria Lagrasta, Caterina Frati, Denise Madeddu, Cristina Caffarra, Daniele Cretella, Maricla Galetti, Silvia La Monica, Federico Quaini, Roberta R. Alfieri, Francesca Saccani, Andrea Cavazzoni, Mara A. Bonelli
Supplementary Tables S1-S5. Table S1: Antiproliferative effects of PI3K inhibitors on SKMES-1 and PIK3CA amplified/mutated clones Tables S2-S4: densitometric analysis of Western blotting of Figure 1D Table S5: Antiproliferative effects of PI3K inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e69b71948c3fa52cb952394674c5eaf
https://doi.org/10.1158/1535-7163.22502805.v1
https://doi.org/10.1158/1535-7163.22502805.v1
Autor:
Andrea Ardizzoni, Pier Giorgio Petronini, Marcello Tiseo, Claudia Fumarola, Pietro Rossetti, Angela Falco, Costanza Annamaria Lagrasta, Caterina Frati, Denise Madeddu, Cristina Caffarra, Daniele Cretella, Maricla Galetti, Silvia La Monica, Federico Quaini, Roberta R. Alfieri, Francesca Saccani, Andrea Cavazzoni, Mara A. Bonelli
Supplementary Figures S1-S5. Figure S1: p-AKT levels in PIK3CA transfected clones Figure S2: Induction of cell death after treatment with PI3K inhibitors Figure S3: Time course evaluation of PI3K/AKT/mTOR pathway activity after exposure to PI3K inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02930cdb13d557e127cf18f88f1ab0ab
https://doi.org/10.1158/1535-7163.22502811
https://doi.org/10.1158/1535-7163.22502811
Autor:
Marcello Tiseo, Federico Quaini, Franco Aversa, Konrad Urbanek, Andrea Ardizzoni, Enrico Maria Silini, Michele Veneziani, Luca Ampollini, Roberta Alfieri, Caterina Frati, Rocchina Vilella, Chiara Mangiaracina, Bruno Lorusso, Costanza Annamaria Lagrasta, Giovanna Armani, Francesco Sogni, Matteo Goldoni, Giovanni Bocchialini, Angela Falco, Denise Madeddu, Giulia Mazzaschi
Purpose: The success of immune checkpoint inhibitors strengthens the notion that tumor growth and regression are immune regulated. To determine whether distinct tissue immune microenvironments differentially affect clinical outcome in non–small cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::283f8b8062f0e685ada4fa6c649dee5b
https://doi.org/10.1158/1078-0432.c.6526485
https://doi.org/10.1158/1078-0432.c.6526485
Autor:
Marcello Tiseo, Federico Quaini, Franco Aversa, Konrad Urbanek, Andrea Ardizzoni, Enrico Maria Silini, Michele Veneziani, Luca Ampollini, Roberta Alfieri, Caterina Frati, Rocchina Vilella, Chiara Mangiaracina, Bruno Lorusso, Costanza Annamaria Lagrasta, Giovanna Armani, Francesco Sogni, Matteo Goldoni, Giovanni Bocchialini, Angela Falco, Denise Madeddu, Giulia Mazzaschi
Clinicopathological correlations. Figure S1: PD-L1 Expression and Clinicopathologic Parameters; Figure S2: PD-L1 Expression and TILs; Figure S3: TILs and Clinicopathological Parameters; Figure S4: NSCLC Immune Microenvironments Based on PD-L1 and TIL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31c040adf5602292e369f263808dee5e
https://doi.org/10.1158/1078-0432.22466943.v1
https://doi.org/10.1158/1078-0432.22466943.v1